Cite
HARVARD Citation
Oaknin, A. et al. (2022). Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study. Journal for immunotherapy of cancer. 10 (1), p. . [Online].